Essential role of the disintegrin-like domain in ADAMTS13 function

Blood

Volumn 113, Issue 22, 2009, Pages 5609-5616

  De Groot, Rens ^a   Bardhan, Ajoy ^a   Ramroop, Nalisha ^a   Lane, David A ^a   Crawley, James T B ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; ASPARTIC ACID; DISINTEGRIN; GLYCINE; LEUCINE; VALINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; MUTANT PROTEIN; RECOMBINANT PROTEIN; VON WILLEBRAND FACTOR;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; SEQUENCE ANALYSIS; AMINO ACID SUBSTITUTION; BIOLOGICAL MODEL; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR GENETICS; MUTAGENESIS; PHYSIOLOGY; PROTEIN PROCESSING; PROTEIN TERTIARY STRUCTURE; SEQUENCE HOMOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADAM PROTEINS; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CATALYTIC DOMAIN; CELLS, CULTURED; DISINTEGRINS; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS; MUTANT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; VON WILLEBRAND FACTOR;

EID: 67049114094     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-11-187914     Document Type: Article

References (52)

1. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424. (Pubitemid 28411134)
2. Leyte A, Verbeet MP, Brodniewicz-Proba T, Van Mourik JA, Mertens K. The interaction between human blood-coagulation factor VIII and von Willebrand factor: Characterization of a high-affinity binding site on factor VIII. Biochem J. 1989;257:679-683. (Pubitemid 19050122)
3. Romijn RA, Bouma B,WuysterW, et al. Identification of the collagen-binding site of the von Willebrand factor A3-domain. J Biol Chem. 2001;276:9985-9991. (Pubitemid 37391904)
4. Romijn RA, Westein E, Bouma B, et al. Mapping the collagen-binding site in the von Willebrand factor-A3 domain. J Biol Chem. 2003;278:15035-15039. (Pubitemid 36799836)
5. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood. 1996; 88:2939-2950. (Pubitemid 26357374)
6. Cruz MA, Diacovo TG, Emsley J, Liddington R, Handin RI. Mapping the glycoprotein Ib-binding site in the von willebrand factor A1 domain. J Biol Chem. 2000;275:19098-19105. (Pubitemid 30422878)
7. Mayadas TN, Wagner DD. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc Natl Acad Sci U S A. 1992;89:3531-3535.
8. Furlan M. Proteolytic cleavage of von Willebrand factor by ADAMTS-13 prevents uninvited clumping of blood platelets. J Thromb Haemost. 2004; 2:1505-1509. (Pubitemid 40186162)
9. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276: 41059-41063. (Pubitemid 37373259)
10. Zheng X, Nishio K, Majerus EM, Sadler JE. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J Biol Chem. 2003;278:30136-30141. (Pubitemid 36962406)
11. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultra-large von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100:4033-4039. (Pubitemid 35396870)
12. Dong JF, Moake JL, Bernardo A, et al. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem. 2003;278:29633-29639. (Pubitemid 36962347)
13. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488-494. (Pubitemid 32938741)
14. Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98:1662-1666.
15. Zhou W, Inada M, Lee TP, et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest. 2005;85:780-788. (Pubitemid 40799707)
16. Suzuki M, Murata M, Matsubara Y, et al. Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. Biochem Biophys Res Commun. 2004;313:212-216. (Pubitemid 37524045)
17. Shang D, Zheng XW, Niiya M, Zheng XL. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood. 2006;108:2207-2215. (Pubitemid 44497501)
18. Turner N, Nolasco L, Tao Z, Dong JF, Moake J. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost. 2006;4:1396-1404. (Pubitemid 43756721)
19. Manea M, Kristoffersson A, Schneppenheim R, et al. Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br J Haematol. 2007;138:651-662. (Pubitemid 47206716)
20. Majerus EM, Zheng X, Tuley EA, Sadler JE. Cleavage of the ADAMTS13 propeptide is not required for protease activity. J Biol Chem. 2003; 278:46643-46648. (Pubitemid 37452240)
21. Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood. 2007;109:1998-2000. (Pubitemid 46348198)
22. Crawley JT, Lane DA, Woodward M, Rumley A, Lowe GD. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost. 2008;6:583-588.
23. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996;87:4235-4244.
24. Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223-4234. (Pubitemid 26152266)
25. Sutherland JJ, O'Brien LA, Lillicrap D, Weaver DF. Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations. J Mol Model (Online). 2004;10:259-270. (Pubitemid 39236649)
26. Plaimauer B, Zimmermann K, Volkel D, et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood. 2002;100:3626-3632. (Pubitemid 35303932)
27. Gao W, Anderson PJ, Sadler JE. Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity. Blood. 2008;112:1713-1719.
28. de Groot R, Lane DA. Shear tango: dance of the ADAMTS13/VWF complex. Blood. 2008;112: 1548-1549.
29. Gardner M, Chion AC, de Groot R, Shah A, Crawley JTB, Lane DA. A functional calcium binding site in the metalloprotease domain of ADAMTS13. Blood. 2009;113:1149-1157.
30. Ai J, Smith P, Wang S, Zhang P, Zheng XL. The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J Biol Chem. 2005;280:29428-29434. (Pubitemid 41177015)
31. Tao Z, Wang Y, Choi H, et al. Cleavage of ultralarge multimers of von Willebrand factor by C-terminal- truncated mutants of ADAMTS-13 under flow. Blood. 2005;106:141-143. (Pubitemid 40967185)
32. Soejima K, Matsumoto M, Kokame K, et al. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage. Blood. 2003;102:3232-3237. (Pubitemid 37314760)
33. Wu JJ, Fujikawa K, McMullen BA, Chung DW. Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor. Proc Natl Acad Sci U S A. 2006;103: 18470-18474. (Pubitemid 44913434)
34. Gao W, Anderson PJ, Majerus EM, Tuley EA, Sadler JE. Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease. Proc Natl Acad Sci U S A. 2006;103: 19099-19104.
35. Shieh HS, Mathis KJ, Williams JM, et al. High resolution crystal structure of the catalytic domain of ADAMTS-5 (aggrecanase-2). J Biol Chem. 2008;283:1501-1507.
36. Gerhardt S, Hassall G, Hawtin P, et al. Crystal structures of human ADAMTS-1 reveal a conserved catalytic domain and a disintegrin-like domain with a fold homologous to cysteine-rich domains. J Mol Biol. 2007;373:891-902.
37. Mosyak L, Georgiadis K, Shane T, et al. Crystal structures of the two major aggrecan degrading enzymes, ADAMTS4 and ADAMTS5. Protein Sci. 2008;17:16-21.
38. Crawley JT, Lam JK, Rance JB, Mollica LR, O'Donnell JS, Lane DA. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood. 2005;105:1085-1093.
39. Zanardelli S, Crawley JT, Chion CK, Lam JK, Preston RJ, Lane DA. ADAMTS13 substrate recognition of von Willebrand factor A2 domain. J Biol Chem. 2006;281:1555-1563.
40. Lam JK, Chion CK, Zanardelli S, Lane DA, Crawley JT. Further characterization of ADAMTS-13 inactivation by thrombin. J Thromb Haemost. 2007;5:1010-1018.
41. Camilleri RS, Cohen H, Mackie IJ, et al. Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. J Thromb Haemost. 2008;6: 331-338.
42. Söding J. Protein homology detection by HMMHMM comparison. Bioinformatics. 2005;21:951-960.
43. Söding J, Remmert M, Biegert A, Lupas AN. HH-senser: exhaustive transitive profile search using HMM-HMM comparison. Nucleic Acids Res. 2006;34:W374-378.
44. O'Donnell JS, McKinnon TA, Crawley JT, Lane DA, Laffan MA. Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood. 2005;106:1988-1991.
45. McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA. N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood. 2008; 111:3042-3049.
46. Takeda S. Three-dimensional domain architecture of the ADAM family proteinases. Semin Cell Dev Biol. 2009; 20:146-152.
47. Takeda S, Igarashi T, Mori H, Araki S. Crystal structures of VAP1 reveal ADAMs' MDC domain architecture and its unique C-shaped scaffold. EMBO J. 2006;25:2388-2396.
48. Igarashi T, Araki S, Mori H, Takeda S. Crystal structures of catrocollastatin/VAP2B reveal a dynamic, modular architecture of ADAM/adamalysin/ reprolysin family proteins. FEBS Lett. 2007; 581:2416-2422.
49. Zhang P, Pan W, Rux AH, Sachais BS, Zheng XL. The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow. Blood. 2007;110:1887-1894.
50. Soejima K, Nakamura H, Hirashima M, Morikawa W, Nozaki C, Nakagaki T. Analysis on the molecular species and concentration of circulating ADAMTS13 in blood. J Biochem (Tokyo). 2006; 139:147-154.
51. Moriguchi-Goto S, Yamashita A, Tamura N, et al. ADAMTS-13 attenuates thrombus formation on type I collagen surface and disrupted plaques under flow conditions. Atherosclerosis. Prepublished on August 13, 2008, as DOI 10.1016/j.atherosclerosis. 2008.07.043.
52. Majerus EM, Anderson PJ, Sadler JE. Binding of ADAMTS13 to von Willebrand factor. J Biol Chem. 2005;280:21773-21778.